Electromedical Technologies Inc (EMED)

[Winsmore]

$EMED Some interesting additional due diligence:

AI Overview:
$EMED As of January 2026, the consolidation of ElectroMedical Technologies (EMED) into Lionheart Health is a centerpiece of Howard Leonhardt’s "roll-up" strategy to take the company public.

Device Integration: WellnessPro Infinity vs. Lionheart 240
The "New" Lionheart 240: The device Howard Leonhardt unveiled on January 8, 2026, is the “First new gen 2025 Model Lionheart 240 Biolectric Stimulator”, which is built on the EMED WellnessPro Infinity™ platform.

Replacement Status: This EMED-manufactured device is effectively replacing the older Mettler Electronics Sys*Stim 240 as the primary hardware platform for Lionheart’s proprietary "cell signaling" software. While the Mettler platform was used as a bridge, the EMED Infinity platform is now the designated standard for Lionheart's 124 planned global medspas.

Significance of Octane Tech Forum: Leonhardt’s presentation at the Octane Aesthetics Tech Forum on January 8, 2026, serves as a high-visibility validation event. Showcasing the final "2025 Model" production unit to industry investors and experts is a standard final step to build institutional confidence before filing for an IPO.


IPO and Roll-up Progress
IPO Timing: Howard Leonhardt previously disclosed plans to file the Lionheart Health IPO in late 2025 or 2026. The current events—including the GetHairMD Open House on January 15, 2026, to demonstrate the HairCell platform—suggest the commercial ecosystem is fully operational, which is often a prerequisite for an IPO announcement.


Status of the Roll-up:

Completed Steps: The joint venture between EMED and Lionheart is established; a $473,000 purchase order from Lionheart to EMED for Infinity devices was executed; and the debt restructuring of EMED to "clean up" the balance sheet for the merger has been completed.

Remaining Steps: The final legal and financial merger of EMED into the Lionheart entity must be finalized. Shareholders typically await a formal "Definitive Agreement" announcement followed by a proxy vote for the acquisition.

Commercial Momentum: With 124 medspa locations opening (including sites in New York, London, and Scottsdale), EMED’s technology is transitioning from a niche pain-management tool to the "engine" of a global longevity and aesthetics brand.

Impending News: Given that Howard Leonhardt is actively presenting the production-ready hardware at major forums this month, a formal acquisition announcement or IPO filing (S-1) is likely the next major milestone on the 2026 roadmap.

------------------------------------------------------------------------


First new gen 2025 Model Lionheart 240 Biolectric Stimulator just arrived at our Orange County, California headquarters after quality release testing in Arizona. Taking it to Octane Aesthetics Tech Forum now!




HairCell™ Launch at Rejuvalase MediSpa in Santa Barbara, CA
and GetHairMD - Santa Barbara licensed clinic training session (see EMED’s device)
Gregory S. Keller MD, FACS
Explore this breakthrough, non-invasive hair growth treatment at our Open House on Jan 15, 2–6 PM.




Speaker Presentations from the first annual Klotho Conference held in Newport Beach, CA September 15-16, 2025
Day 2 11 Dr .Gregory Keller



The reasons for holding the Klotho Conference include both scientific advancement and commercial strategy:

Building Commercial Alignment: The conference was identified as a platform for building a community and commercial alignment across the longevity space, as Lionheart Health is actively pursuing a licensing program for its Klotho-related technologies.

---Showcasing Research and Products: Lionheart Health and its partners used the conference to present their specific research and products, such as bioelectric stimulation devices that have shown an ability to increase Klotho levels.

---Investor Relations: Given the context of the upcoming IPO and the inclusion of "investors panel discussion" and "corporate presentations" in the related conference agenda, the event was a strategic opportunity to build awareness and confidence among investors and analysts in the commercial viability of Klotho-based treatments.

Scientific and Clinical Collaboration: The event gathered leading researchers, clinicians, and biotech innovators to share data, protocols, and outcomes related to the Klotho protein and its therapeutic potential in conditions ranging from neurodegenerative diseases to cancer and kidney disease.

Advancing the Field: It served as an interactive forum for discussions and debate on the future of Klotho-based therapies and diagnostics, helping to move the science from theory to translation.